midazolam has been researched along with digoxin in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.13) | 18.2507 |
| 2000's | 15 (31.91) | 29.6817 |
| 2010's | 21 (44.68) | 24.3611 |
| 2020's | 10 (21.28) | 2.80 |
| Authors | Studies |
|---|---|
| Fischer, H; Huwyler, J; Poli, S; Schwab, D; Tabatabaei, A | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bi, YA; Chupka, J; Duignan, DB; Kimoto, E; Xiao, Y | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
| Hu, J; Hu, Q; Kong, X; Liu, J; Luo, G; Shen, H; Wang, C; Wu, T; Wu, X; Xiang, Q; Xu, Y; Zhang, C; Zhang, Y; Zhuang, X; Zou, L | 1 |
| Augsburger, M; Giroud, C; Mangin, P; Rivier, L; Tracqui, A | 1 |
| Andersen, VC; Sonne, J | 1 |
| Achira, M; Crespi, CL; Ito, K; Kato, Y; Kawahara, I; Sugiyama, Y; Suzuki, H | 1 |
| Katoh, M; Nakajima, M; Yamazaki, H; Yokoi, T | 1 |
| Gilbert, D; Jolley, S; LeCluyse, EL; Milad, MA; Rose, KA; Sahi, J; Stern, RH; Stilgenbauer, L; Wang, H; Zheng, X | 1 |
| Becquemont, L; Burk, O; Drescher, S; Eichelbaum, M; Fromm, MF; Glaeser, H; Heinkele, G; Hitzl, M; Hofmann, U; Murdter, TE; Schaefer, C; Simon, N; Verstuyft, C | 1 |
| Hoffer, CJ; Kharasch, ED; Kirby, B; Narang, VS; Thummel, KT; Unadkat, JD | 1 |
| Cederberg, J; Dahl, ML; Karlsson, MO; Magnusson, MO; Sandström, R | 1 |
| Buchanan, ML; Carr, DB; Easterling, TR; Fishbein, DP; Hebert, MF; Kirby, B; Rutherford, T; Thummel, KE; Unadkat, JD | 1 |
| Baba, K; Hamahata, Y; Hayashi, M; Iwanaga, K; Kakemi, M; Miyazaki, M; Shibano, M; Taniguchi, M | 1 |
| Doroshyenko, O; Fätkenheuer, G; Frank, D; Fuhr, U; Hein, W; Jetter, A; Kirchheiner, J; Klaassen, T; Schömig, E; Seeringer, A; Wyen, C | 1 |
| Cai, X; Chu, X; Ding, Y; Evers, R; Gibson, C; Reitman, ML; Roupe, K; Stoch, A; Stone, JA; Venkatasubramanian, R; Wagner, JA; Witter, R; Yabut, J; Zajic, S | 1 |
| Bi, H; Huang, L; Huang, M; Qin, X; Xiao, H; Xue, X; Zhong, G | 1 |
| Bi, XL; Chen, LT; Di, LQ; Du, Q; Zhou, W | 1 |
| Alves, K; Chandorkar, G; Farmer, HF; Garg, V; Smith, F; van Heeswijk, RP | 1 |
| Barter, Z; Jamei, M; Neuhoff, S; Rostami-Hodjegan, A; Turner, DB; Yeo, KR | 1 |
| Aharchi, F; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Onkelinx, J; Peeters, M; Stevens, T; Van Solingen-Ristea, RM | 1 |
| Aspeslet, LJ; Foster, RT; Freitag, DG; Huizinga, RB; Larouche, R; Ling, SY; Mayo, PR | 1 |
| Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD | 1 |
| Chavan, AB; Dubey, N; Gilmartin, GS; Higgins, M; Li, C; Luo, X; Mahnke, L; Robertson, SM | 1 |
| Johansson, S; Leese, PT; Li, Y; Lisbon, E; Martin, P; Mathews, D; Oliver, S; Read, J; Steinberg, M | 1 |
| Chan, LN; Flum, DR; Horn, JR; Lin, YS; Oelschlager, BK; Patton, KK; Shen, DD; Tay-Sontheimer, JC; Trawick, D | 1 |
| Jin, F; Moyer, C; Murray, B; Ramanathan, S; Robeson, M; Wilbert, S; Zhou, H | 1 |
| Edwards, JE; Eliot, L; Karan, S; MacConell, L; Parkinson, A | 1 |
| Britz, H; Eissing, T; Frechen, S; Hanke, N; Lehr, T; Moj, D; Wendl, T | 1 |
| Chan, LN; Chen, KF; Lin, YS | 1 |
| Kawaguchi, A; Nakamura, T; Shimizu, H | 1 |
| Balazki, P; Baumgart, J; Beelen, DW; Böhm, S; Hemmelmann, C; Hilger, RA; Martins, FS; Ring, A; Schaller, S | 1 |
| Henderson, LM; Ragueneau-Majlessi, I; Steinbronn, CE; Yeung, CK; Yu, J | 1 |
| Ang, DSW; Ang, TL; Benech, H; Koo, SH; Lee, EJD; Pruvost, A; Soon, GH | 1 |
| Abdulrasool, LI; Endres, CJ; Lee, A; Mayor, JG; Rustia, EL; Sun, H; Topletz-Erickson, A; Walker, L | 1 |
| Barth, A; Brimhall, DB; Dumont, EF; Nguyen, D; Perry, CR; Shabbir, S; Srinivasan, M; Swift, B; Thomas, S; Zamek-Gliszczynski, MJ | 1 |
| Aarnoutse, RE; Boeree, MJ; Coenen, MJH; Colbers, A; Dawson, R; Diacon, AH; Fuhr, U; Jager, Vd; Narunsky, K; Padayachee, SD; Phillips, PPJ; Stemkens, R; Svensson, EM; Te Brake, LHM; van Beek, SW | 1 |
3 review(s) available for midazolam and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Drug metabolism in the small intestine--the significance for biological availability].
Topics: Animals; Biological Availability; Cyclosporins; Cytochrome P-450 Enzyme System; Digoxin; Enzyme Inhibitors; GABA Modulators; Glycoproteins; Humans; Intestinal Absorption; Intestinal Diseases; Intestinal Mucosa; Intestine, Small; Midazolam; Models, Biological; Pharmaceutical Preparations | 2000 |
Analysis of Drug-Drug Interaction Labeling Language and Clinical Recommendations for Newly Approved Drugs Evaluated With Digoxin, Midazolam, and S-Warfarin.
Topics: Digoxin; Drug Interactions; Humans; Language; Midazolam; Pharmaceutical Preparations; Product Labeling; Warfarin | 2021 |
12 trial(s) available for midazolam and digoxin
| Article | Year |
|---|---|
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Digoxin; Enzyme Activators; Humans; In Vitro Techniques; Intestinal Mucosa; Intestines; Leukocytes; Male; Midazolam; RNA, Messenger; Ursodeoxycholic Acid | 2006 |
Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
Topics: Adolescent; Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Digoxin; Female; Humans; Male; Midazolam | 2006 |
Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.
Topics: Adult; Anesthetics, Intravenous; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiotonic Agents; Creatinine; Cytochrome P-450 CYP3A; Digoxin; Enzyme Inhibitors; Female; Gas Chromatography-Mass Spectrometry; Genotype; Humans; Hypnotics and Sedatives; Midazolam; Postpartum Period; Pregnancy; Pregnancy Trimester, Third | 2008 |
Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.
Topics: Adolescent; Adult; Antiviral Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Oligopeptides; Protease Inhibitors; Young Adult | 2012 |
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Nitriles; Omeprazole; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Theophylline; Warfarin; Young Adult | 2014 |
Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Female; Humans; Ketoconazole; Male; Midazolam; Middle Aged; Verapamil | 2014 |
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Topics: Adult; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Felodipine; Female; Genotype; Humans; Losartan; Male; Midazolam; Omeprazole; Young Adult | 2014 |
Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein.
Topics: Adolescent; Adult; Aminophenols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Contraceptives, Oral, Combined; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Digoxin; Double-Blind Method; Drug Interactions; Ethinyl Estradiol; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Midazolam; Middle Aged; Norethindrone; Progesterone; Quinolones; Rosiglitazone; Thiazolidinediones; Young Adult | 2015 |
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Topics: Adolescent; Adult; Area Under Curve; Digoxin; Drug Interactions; Female; Humans; Male; Metformin; Midazolam; Middle Aged; Omeprazole; Piperidines; Quinazolines; Ranitidine; Young Adult | 2014 |
Clinical drug interaction profile of idelalisib in healthy subjects.
Topics: Adult; Antineoplastic Agents; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Purines; Quinazolinones; Rifampin; Rosuvastatin Calcium; Young Adult | 2015 |
Drug-Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Mineralocorticoid Receptor Antagonists; Warfarin; Young Adult | 2020 |
Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam, and digoxin) approach to estimate hepatic drug detoxification capability and dosage requirements after a single oral dosing in healthy Chinese volunteers.
Topics: Caffeine; China; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Healthy Volunteers; Humans; Midazolam; Omeprazole; Tolbutamide | 2022 |
32 other study(ies) available for midazolam and digoxin
| Article | Year |
|---|---|
Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cells, Cultured; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Indicators and Reagents; Mice; Models, Molecular; Rhodamines; Species Specificity; Swine | 2003 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Characterization of digoxin uptake in sandwich-cultured human hepatocytes.
Topics: Animals; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biological Transport; Cells, Cultured; Digoxin; HEK293 Cells; Hepatocytes; Humans; Liver; Membrane Transport Proteins; Oocytes; Organic Anion Transporters; Transfection; Xenopus laevis | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; CREB-Binding Protein; Drug Design; Humans; Indolizidines; Male; Mice; Mice, SCID; Microsomes, Liver; Models, Molecular; Molecular Docking Simulation; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2022 |
Car crash after massive ingestion of digoxin and midazolam.
Topics: Accidents, Traffic; Adult; Alcohol Drinking; Autopsy; Cardiotonic Agents; Digoxin; Humans; Hypnotics and Sedatives; Male; Midazolam; Substance-Related Disorders | 1998 |
Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cell Line; Cyclosporins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Digoxin; Dose-Response Relationship, Drug; Humans; Hydroxylation; Indans; Microsomes; Midazolam; Mixed Function Oxygenases; Piperazines; Recombinant Proteins; Transfection | 2000 |
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Topics: Amiodarone; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Digoxin; Enzyme Inhibitors; GABA Modulators; Gonadal Steroid Hormones; Humans; LLC-PK1 Cells; Midazolam; Mixed Function Oxygenases; Nifedipine; Phthalazines; Swine; Testosterone | 2001 |
Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.
Topics: Acetamides; Acetates; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Digoxin; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Gene Expression; Hepatocytes; Humans; Microsomes, Liver; Midazolam; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Sulfonamides; Sulfonic Acids | 2003 |
Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caffeine; Carbamazepine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Digoxin; Enzyme Induction; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Substrate Specificity | 2008 |
Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein.
Topics: Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Furocoumarins; Humans; Medicine, Kampo; Midazolam; Quinidine | 2010 |
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Dextromethorphan; Digoxin; Down-Regulation; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Midazolam; Middle Aged; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Digoxin; Drug Interactions; Humans; Male; Midazolam; Middle Aged; Models, Biological; Organic Anion Transporters, Sodium-Independent; Research Design; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2011 |
Rapid and simultaneous measurement of midazolam, 1'-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: application to an in vivo study to simultaneously measure P-glycoprotein and cytochrome P450 3A activity.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Calibration; Cardiotonic Agents; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Stability; Limit of Detection; Male; Midazolam; Random Allocation; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
[Intestinal absorption of forsythoside A by rat circulation in situ].
Topics: Animals; Colon; Cyclosporine; Digoxin; Dose-Response Relationship, Drug; Duodenum; Edetic Acid; Glycosides; Hydrogen-Ion Concentration; Ileum; Intestinal Absorption; Jejunum; Male; Mannitol; Midazolam; Rats; Rats, Sprague-Dawley | 2010 |
Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Topics: Adjuvants, Anesthesia; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B; Computer Simulation; Digoxin; Drug Interactions; Enzyme Inhibitors; Humans; Midazolam; Models, Biological; Permeability; Rifampin; Verapamil | 2013 |
Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Digoxin; Female; Gastric Bypass; Gastrointestinal Absorption; Humans; Longitudinal Studies; Male; Midazolam; Middle Aged; Obesity; Pilot Projects; Prospective Studies | 2015 |
Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Topics: Adult; Aged; Aged, 80 and over; Caffeine; Chenodeoxycholic Acid; Cholangitis; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Midazolam; Middle Aged; Omeprazole; Rosuvastatin Calcium; Warfarin | 2017 |
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Topics: Alfentanil; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Itraconazole; Midazolam; Models, Biological; Rifampin | 2018 |
PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Topics: Acetaminophen; Administration, Oral; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Gastric Bypass; Gastrointestinal Absorption; Hepatobiliary Elimination; Humans; Intestinal Elimination; Metabolic Clearance Rate; Midazolam; Models, Biological; Obesity, Morbid; Postoperative Period; Triazoles; Verapamil | 2020 |
Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Busulfan; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Midazolam; Models, Biological; Omeprazole; Pharmaceutical Preparations | 2022 |
Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Digoxin; Drug Interactions; Gemfibrozil; Healthy Volunteers; Humans; Itraconazole; Midazolam; Oxazoles; Pyridines; Quinazolines; Rifampin; Tolbutamide | 2022 |
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters.
Topics: Cimetidine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Itraconazole; Membrane Transport Proteins; Midazolam; Models, Biological; Pharmaceutical Preparations; Rifampin | 2023 |
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Topics: Adult; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Digoxin; Drug Interactions; Humans; Midazolam; Omeprazole; Rifampin; Tolbutamide; Tuberculosis, Pulmonary | 2023 |